Data in Brief (Apr 2022)

Data of Nebivolol on oxidative stress parameters in hypertensive patients

  • Helena C. Barroso,
  • Murilo E. Graton,
  • Simone R. Potje,
  • Jéssica A. Troiano,
  • Lilian X. Silva,
  • Ana Cláudia M.S. Nakamune,
  • Cristina Antoniali

Journal volume & issue
Vol. 41
p. 107913

Abstract

Read online

Oxidative stress is a key feature in hypertension, since reactive oxygen species are involved in all stages of cardiovascular diseases. Saliva is a body fluid that can be used to investigate alterations in the oxidative system with several specific advantages over blood. Nebivolol is a third-generation selective β1-adrenergic receptor antagonist that promotes vasodilation and has been shown to reduce oxidative stress in pre-clinical and clinical studies. The use of Nebivolol in different periods of treatment demonstrated that it is an efficient anti-hypertensive drug. We evaluated the oxidative stress biomarkers and the enzymatic and non-enzymatic antioxidant systems in saliva of hypertensive patients before and after the use of anti-hypertensive therapeutic doses of Nebivolol, since saliva can be used as an auxiliary tool to analyze parameters of oxidative stress.

Keywords